Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucia B Jilaveanu

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Journal of Bacteriology|December 15, 2005
SecA dimer cross-linked at its subunit interface is functional for protein translocationLucia B Jilaveanu, Donald Oliver
The Journal of Biological Chemistry|December 15, 2006
In vivo membrane topology of Escherichia coli SecA ATPase reveals extensive periplasmic exposure of multiple functionally important domains clustering on one face of SecALucia B Jilaveanu, Donald B Oliver
Proceedings of the National Academy of Sciences of the United States of America|May 18, 2005
Dimeric SecA is essential for protein translocationLucia B Jilaveanu, Christopher R Zito, Donald Oliver
Current Cancer Drug Targets|December 11, 2012
Studies of NVP-BEZ235 in melanomaJoshua A Sznol, Lucia B Jilaveanu, Harriet M Kluger
Clinics in Dermatology|November 3, 2009
Chemotherapy and biologic therapies for melanoma: do they work?Lucia B Jilaveanu, Saadia A Aziz, Harriet M Kluger
Clinics in Dermatology|April 24, 2013
Advances in therapy for melanoma brain metastasesJaclyn C Flanigan, Lucia B Jilaveanu, Veronica L Chiang, et al.
Molecular Cancer|March 5, 2014
MEK targeting in N-RAS mutated metastatic melanomaJaykumar Thumar, David Shahbazian, Saadia A Aziz, et al.
Oncotarget|June 28, 2014
NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinomaEva Giesen, Lucia B Jilaveanu, Fabio Parisi, et al.
Current Opinion in Neurology|October 3, 2019
Complications associated with immunotherapy for brain metastasesThuy T Tran, Lucia B Jilaveanu, Antonio Omuro, et al.
Biomed Research International|October 9, 2015
MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway InhibitorsBrian Shuch, Ryan Falbo, Fabio Parisi, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Journal of Bacteriology|December 15, 2005
SecA dimer cross-linked at its subunit interface is functional for protein translocationLucia B Jilaveanu, Donald Oliver
The Journal of Biological Chemistry|December 15, 2006
In vivo membrane topology of Escherichia coli SecA ATPase reveals extensive periplasmic exposure of multiple functionally important domains clustering on one face of SecALucia B Jilaveanu, Donald B Oliver
Proceedings of the National Academy of Sciences of the United States of America|May 18, 2005
Dimeric SecA is essential for protein translocationLucia B Jilaveanu, Christopher R Zito, Donald Oliver
Current Cancer Drug Targets|December 11, 2012
Studies of NVP-BEZ235 in melanomaJoshua A Sznol, Lucia B Jilaveanu, Harriet M Kluger
Clinics in Dermatology|November 3, 2009
Chemotherapy and biologic therapies for melanoma: do they work?Lucia B Jilaveanu, Saadia A Aziz, Harriet M Kluger
Clinics in Dermatology|April 24, 2013
Advances in therapy for melanoma brain metastasesJaclyn C Flanigan, Lucia B Jilaveanu, Veronica L Chiang, et al.
Molecular Cancer|March 5, 2014
MEK targeting in N-RAS mutated metastatic melanomaJaykumar Thumar, David Shahbazian, Saadia A Aziz, et al.
Oncotarget|June 28, 2014
NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinomaEva Giesen, Lucia B Jilaveanu, Fabio Parisi, et al.
Current Opinion in Neurology|October 3, 2019
Complications associated with immunotherapy for brain metastasesThuy T Tran, Lucia B Jilaveanu, Antonio Omuro, et al.
Biomed Research International|October 9, 2015
MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway InhibitorsBrian Shuch, Ryan Falbo, Fabio Parisi, et al.
Pageof 5